Top Active Companies to Watch: Crown Marketing, Herbalife, Novogen, GNC, Pfizer and Infinity Pharmaceuticals

   Top Active Companies to Watch: Crown Marketing, Herbalife, Novogen, GNC,
                     Pfizer and Infinity Pharmaceuticals

  PR Newswire

  CORAL SPRINGS, Florida, February 20, 2013

CORAL SPRINGS, Florida, February 20, 2013 /PRNewswire/ -- reports on active HealthCare Companies to watch today:
Crown Marketing, Herbalife Ltd. (NYSE: HLF ), Novogen Ltd. (NASDAQ: NVGN ),
GNC Holdings, Inc. (NYSE: GNC ), Pfizer Inc. (NYSE: PFE ) and Infinity
Pharmaceuticals, Inc. (NASDAQ: INFI ).

Crown Marketing, currently trading on the OTCQB market, traded over 880,000
shares yesterday, exceeding its average daily volume. To see the latest news
and charts for Crown, please go to . News issued this morning
from Crown Marketing was the company announced that patents for its Controlled
Drug Delivery Technology (CDDT) have been approved and registered in Mexico.
Mexico's pharmaceutical industry faces unique challenges. According to an
American Enterprise Institute study, Mexico's$15.5 billion market is plagued
by counterfeit goods. Illicit activity in Mexico's pharmaceutical industry is
estimated at roughly USD 1.9 billion per year-with counterfeiting representing
81 percent of that illicit market. This is a situation where CWNM believes
its unique technology could have a significant impact. For more details
regarding Crown's CDDT applications, go to 

To read all the latest headlines for Crown, go to

Herbalife Ltd. (NYSE: HLF ) reported late yesterday the company's fourth
quarter net sales of $1.1 billion, reflecting an increase of 20 percent
compared to the same time period in 2011 on volume point growth of 18 percent.
Net income for the quarter of $117.8 million, or $1.05 per diluted share,
compares to 2011 fourth quarter net income of $105.4 million and EPS of $0.86,
respectively. Herbalife shares soared yesterday in trading after documents
revealed corporate raider Carl Icahn's huge stake in the Los Angeles-based
maker of nutritional foods and supplements.  Shortly after the opening bell
on Wall Street yesterday, Herbalife shares added $4.72, or 12.3%, to $42.99,
closing at $39.74.

Novogen Ltd. (NASDAQ: NVGN ) experience heavy trading in the markets yesterday
closing up over 200% on 2.29Million shares traded. Novogen uses a virtual
model in its approach to drug discovery and development. The new lean
corporate structure focuses on its human capital in-place of expensive
facilities and equipment that can be outsourced. The drug discovery strategies
and plans are created in-house then executed by a number of leading external
research organizations. This affords Novogen immediate access to cutting edge
facilities, skills, equipment and scale-up processes. This strategy drives
efficiencies over the drug discovery/development continuum.

GNC Holdings, Inc. (NYSE: GNC ), hit a new 52-week high Tuesday as it is
closed at $42.19, above its previous 52-week high with over 3.9 million shares
traded as of the close. Average volume has been two million shares over the
past 30 days. GNC, the nation's largest specialty retailer of health and
wellness products, announced yesterday that its employees and customers
donated a total of $3.1 million during these past few months to support the
St. Jude Children's Research Hospital Thanks and Giving campaign. The
campaign, now in its ninth year, builds awareness of and raises funds for the
lifesaving research and treatment done at St. Jude to help children fighting
cancer and other deadly diseases.

Pfizer Inc. (NYSE: PFE ), a biopharmaceutical company, engages in the
discovery, development, manufacture, and sale of medicines for people and
animals worldwide. Pfizer pushed the pharma industry higher in trading
yesterday making a featured drugs winner for the day. By the end of trading,
Pfizer rose 42 cents (1.5%) to $27.71 on average volume. Throughout the day,
28.4 million shares of Pfizer exchanged hands as compared to its average daily
volume of 32.5 million shares. The stock ranged in a price between
$27.38-$27.71 after having opened the day at $27.40 as compared to Friday's
trading day's close of $27.29.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI ) is an innovative drug discovery
and development company seeking to discover, develop and deliver to patients
best-in-class medicines for diseases with significant unmet need. Infinity
combines proven scientific expertise with a passion for developing novel small
molecule drugs that target emerging disease pathways. Infinity
Pharmaceuticals' shares spiked 16 percent Tuesday after Morgan Stanley issued
a bullish assessment of the Cambridge-based company's prospects and pricing
potential. As of Tuesday, Morgan Stanley was promoting an "Overweight"
recommendation to investors in Infinity stock while also assigning the company
a $47 price-per-share target. Infinity (Nasdaq: INFI) saw its stock rise to
$41.48 a share yesterday before closing at $41.10   is leading provider of third party publishing &
news dissemination services. If you would like more information regarding our
news coverage solutions, please visit  
for more details.

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities.  The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks.


This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information: Company:  FN Media Group, LLC Contact email: U.S. Phone: +1-954-345-0611 URL:
Press spacebar to pause and continue. Press esc to stop.